SAN FRANCISCO, Oct. 17, 2011 /PRNewswire/ -- Sutro Biopharma, a biopharmaceutical company developing novel and biosuperior protein therapeutics with improved pharmaceutical properties, today announced that the company's proprietary biochemical protein synthesis technology platform for the synthesis and manufacturing of novel protein therapeutics will be presented at the BioProduction 2011 conference in Berlin.
Trevor Hallam, Ph.D., chief scientific officer of Sutro, will present the capabilities of the company's platform as a design and production tool for hundreds of variants of potential protein therapeutics, including those with site-specifically incorporated non-natural amino-acids as well as those that cannot be synthesized with conventional technologies. Proteins can be expressed at research scale in a rapid parallel manner in several hours, and the linear scalability of the system allows for seamless and prompt scale up for use in clinical studies. Sutro is establishing a current Good Manufacturing Practice (cGMP) facility for the production of clinical supplies of materials using their biochemical protein synthesis platform that will be on line in the first half of 2012. The featured presentation will take place at 4:20 p.m. CEST on Oct. 20.
"I am pleased to present Sutro's open, cell-free protein synthesis platform and its application to this broad audience at the BioProduction meeting," said Trevor Hallam, Ph.D. "Our technology platform enables the expression of proteins that cannot be expressed with other expression systems, including novel antibody-drug conjugates and other proteins with site-specific modifications. We are currently establishing our own drug pipeline and are also looking forward to discuss potential collaborations with new partners."
About Sutro Biopharma
Sutro Biopharma is a biopharmaceutical company that develops and designs novel protein therapeutics and biosuperiors that have site-directed
|SOURCE Sutro Biopharma|
Copyright©2010 PR Newswire.
All rights reserved